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Abstract Non-alcoholic fatty liver disease (NAFLD) is a
multifactorial condition that encompasses a wide spectrum
of liver abnormalities ranging from simple liver steatosis to
steatohepatitis (non-alcoholic steatohepatitis), which may be
associated with fibrosis and progress to cirrhosis and end-
stage liver disease. NAFLD has recently become the most
common cause of chronic liver disease in children and ado-
lescents. NAFLD prevalence, alongside obesity, continues to
increase among pediatric patients. Obesity is believed to rep-
resent a major risk factor for NAFLD, which is considered to
be the liver presentation of the metabolic syndrome. Although
the pathogenesis of NAFLD is not fully understood, the
notion that multiple factors affect disease development and
progression is widely accepted. Both genetic background and
environmental factors contribute to NAFLD development. A
more complete understanding of the pathogenesis may aid in
developing non-invasive diagnostic tools and identifying new
therapeutic targets. Liver biopsy currently remains the gold
standard for NAFLD diagnosis and staging. Although lifestyle
and diet modifications are key in NAFLD treatment, the
development of new pharmacological therapies is crucial
for patients who are unresponsive to first-line therapy.
Conclusion : Pediatric NAFLD is an increasing public health
issue that remains underdiagnosed. A large-scale screening in
the high-risk population, especially among the overweight
pediatric patients, should be considered, including measure-
ment of serum transaminases and liver ultrasound. It is crucial
to treat this condition as soon as possible in order to avoid the
progression to end-stage liver disease.
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Introduction
Over the past few decades, non-alcoholic fatty liver disease
(NAFLD) has become the most common cause of chronic liver
disease among children and adolescents in Western countries,
with cases documented in children as young as 3 years of age
[15]. NAFLD refers to a wide spectrum of liver abnormalities
ranging from simple liver steatosis (fat accumulation in the
liver) to steatohepatitis (non-alcoholic steatohepatitis, NASH),
which may be associated with fibrosis and progress to cirrhosis
and end-stage liver disease.
In 1952, S. Zelman documented liver lesions compatible
with NASH for the first time [73]. Ludwig et al. used the term
“NASH” in 1980 [32]. Three years later, the first pediatric
NASH cases were reported [38].
NAFLD prevalence is increasing, alongside obesity, essen-
tially because of sedentary lifestyles and hypercaloric diets
[4]. NAFLD is considered the hepatic manifestation of the
metabolic syndrome, which is characterized by insulin resis-
tance, visceral obesity, hypertension, dyslipidemia, and abnor-
malities of fasting serum glucose levels. Pediatric patients
with NAFLD have been shown to exhibit higher levels of
insulin, total cholesterol, triglycerides, low-density lipoprotein
cholesterol, and fasting glucose, as well as higher blood
pressure values than obese children without NAFLD. More-
over, children with metabolic syndrome are more likely to
display NAFLD than obese children without metabolic syn-
drome [61]. NAFLD is also associated with an increased risk
of developing cardiovascular diseases [52]. NAFLD patients
have a higher prevalence of atherosclerosis [50].
NAFLD pathogenesis is not yet fully understood, but the
hypothesis that multiple factors contribute to disease develop-
ment and progression is now widely accepted [3].
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Histological liver analysis remains the gold standard to
differentiate between simple steatosis and NASH, to perform
disease staging, and to exclude other causes of chronic liver
diseases[66].
No effective treatment is currently available. In children,
weight loss and physical activity are considered first-line
treatment. However, a poor compliance to lifestyle modifica-
tions is a daily reality. Developing new treatments to stop the
disease from progressing to end-stage liver disease appears
therefore crucial. Over the past several years, new pharmaco-
logical treatments have been developed and tested [5].
In this review, we will present an overview of current
knowledge regarding the pathogenesis, diagnostic methods,
histological features, and treatment of pediatric NAFLD.
Epidemiology
According to epidemiological data, NAFLD may affect 3–
10 % of pediatric patients, with a male-to-female ratio of 2:1
[4]. Obesity is thought to be the main risk factor for pediatric
NAFLD. In obese children, NAFLD prevalence may reach
70–80 % [36].
However, true NAFLD prevalence in children is unknown.
Indeed, only a few studies have been conducted with children
and adolescents. Moreover, in most studies on NAFLD prev-
alence in children, indirect measures such as blood tests and
ultrasound were used as screening tools. Serum alanine ami-
notransferase (ALT) sensitivity and specificity are poor (64
and 81 %, respectively). Sensitivity is low, as some NAFLD
children may present ALT values in the normal range [33].
Furthermore, various cutoff levels are cited in the literature.
Ultrasound exhibits limited detection capabilities: this tool
identifies only high levels of fat (>30 %) and cannot detect
fibrosis [56]. Liver histology, the most relevant diagnosis
criterion, is rarely used for screening [71].
More accurate estimates of disease prevalence in the USA
were obtained from an autopsy study in San Diego. Steatosis
was found in 9.6 % of individuals aged 2 to 19 years and in
38 % of obese children autopsied between 1993 and 2003
[59]. A liver biopsy study during gastric bypass surgery was
performed in morbidly obese adolescents. This cohort showed
a high NAFLD prevalence (83 %), with 20 % of participants
meeting the histological criteria for NASH [72].
NAFLD prevalence appears to increase with age, with a
mean age at diagnosis between 11 and 13 years [71]. This
tendency is likely explained by adolescent hormonal changes,
which result in an increase in serum insulin levels and fat
accumulation in the liver [55]. Ethnicity may also affect
NAFLD prevalence. Hispanic children have the highest
NAFLD prevalence (36 %), whereas African American chil-
dren are less affected (14 %), although both populations
exhibit similar obesity rates [21]. These discrepancies may
be accounted for by genetic factors or environmental features,
such as diet and exercise [16].
The prognosis of pediatric NAFLD is still unknown, as
only a limited number of long-term follow-up studies have
been conducted to date [3]. The first long-term study with a
follow-up period of up to 20 years, which assessed overall
survival of NAFLD pediatric patients, reported a shorter long-
term survival than non-affected patients [71].
Pathogenesis
NAFLDwas initially considered a two-hit process. At present,
however, the notion that NAFLD pathogenesis is multifacto-
rial with many factors affecting disease development and
progression is widely accepted. The “multiple-hit” hypothesis
is currently the established pathogenetic model [17].
At disease onset, NAFLD is characterized by fat accumu-
lation in the liver (steatosis) and insulin resistance, influenced
by genetic susceptibility, epigenetic mechanisms, a sedentary
lifestyle, and hypercaloric diets [48]. Hepatic triglyceride
accumulation results from increased delivery of free fatty
acids to the liver, increased lipogenesis, and impaired fatty
acid metabolism in hepatocytes. Hepatic fat accumulation has
been shown to exacerbate insulin resistance by interfering
with phosphorylation of insulin receptor substrates [57]. Free
fatty acid accumulation and insulin resistance may predispose
the fatty liver to secondary hits, including oxidative stress,
mitochondrial dysfunction, pro-inflammatory cytokines im-
balance, and stellate cells activation, which lead to necro-
inflammation and fibrosis [64] (Fig. 1).
The gut’s critical role in NAFLD pathogenesis has recently
been given consideration. In NAFLD, an alteration of gut
microbiota and enhanced gut permeability increase liver ex-
posure to gut-derived bacterial products, such as lipopolysac-
charides. These products stimulate innate immune receptors
(Toll-like receptors), which leads to activation of the signal-
ling pathways involved in liver inflammation and fibrogenesis
[22].
Hepatic stellate cells are considered the main extracellular
matrix-producing cells during NASH development. However,
the hepatic progenitor cell compartment of the liver has re-
cently been shown to be expanded in children with NAFLD.
Hepatic progenitor cell activation appears to play a role in
liver response to oxidative stress and is correlatedwith fibrosis
and NASH progression [43].
Adipocytokines, including adiponectin, leptin, resistin, and
tumour necrosis factor-alpha (TNF-alpha), also appear to be
involved in the progression of simple steatosis to NASH. Adi-
pocytes or inflammatory cells infiltrating the adipose tissue in
insulin resistance conditions are responsible for adipocytokine
secretion. Leptin may activate hepatic stellate cells and suppress
their apoptosis.
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The expansion of adipose tissue, and particularly that of
visceral fat, is associated with a decrease in the release of
insulin-sensitizing and anti-inflammatory cytokines and an
increase in the release of pro-inflammatory molecules [34].
TNF-alpha and IL-6 levels are often elevated in the liver and
blood of NASH patients. These cytokines are involved in
Kupffer cell recruitment and activation, as well as in hepatic
stellate cell activation in myofibroblasts [48].
To summarize, NAFLD results from crosstalk between mul-
tiple organs, including adipose tissue, the pancreas, gut, and liver.
Diagnosis of NAFLD/NASH
NAFLD is often diagnosed in asymptomatic patients, with
unexplained increased serum aminotransferase or gamma-
glutamyl transpeptidase values detected during routine check-
ups. However, some patients may suffer from abdominal pain;
hepatomegaly may be present, whereas splenomegaly is rare.
For diagnosing NAFLD, it is necessary to eliminate other
liver disease etiologies, such as hepatitis B and C, autoim-
mune hepatitis, drug-induced liver injury, Wilson’s disease,
alpha 1-antitrypsin deficiency, inborn errors of fatty acid or
carnitine metabolism, peroxisomal disorders, lysosomal stor-
age disorders, and cystic fibrosis. However, positive serum
autoantibodies (antinuclear and anti-SMA) are often present in
NAFLD pediatric patients, in the absence of autoimmune
hepatitis. Their clinical significance remains unclear [3].
Indirect markers
Enhanced ALT levels are common among pediatric patients
with NAFLD [51]. Aminotransferase levels may range from
normal to four to six times the upper limit of normal. Mild
aminotransferase elevation is usually observed in NAFLD
patients (1.5–2 times the upper limit of normal) [8]. However,
circulating aminotransferases levels are frequently normal in
children with NAFLD and NASH. Furthermore, normal ami-
notransferase levels do not exclude possible fibrosis or cirrho-
sis. Together with fibrosis progression and steatosis reduction,
aminotransferase levels may decrease. Therefore, this test is
not representative of NAFLD severity. Moreover, dietary
habits and hyperalimentation may impact on serum amino-
transferase levels [24].
Lipid profiles, fasting glucose, and insulin levels should be
evaluated in children with NAFLD, who often present with
several metabolic syndrome components [3].
Imaging techniques
Ultrasonography (US) is the most common imaging modality
for fatty liver detection. US has several advantages, such as its
relatively low cost and wide availability. A recent study dem-
onstrated liver US efficacy for quantifying steatosis in chil-
dren. A strong correlation between US steatosis scores and
steatosis severity on liver biopsy was observed [62]. However,
US sensitivity decreases when the liver contains <30 % fat or
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in individuals with BMI ≥40 [56]. Moreover, US cannot
exclude steatohepatitis or fibrosis.
Computed tomography is a more sensitive technique for
detecting fat in the liver, but its use is not recommended in
children because of radiation exposure. Magnetic resonance im-
aging is also relatively sensitive in liver fat quantification, al-
though its costs and the need for sedation in young children limit
its clinical utility. Finally, none of these imaging tools exhibits
sufficient sensitivity and specificity to differentiate between sim-
ple steatosis and NASH or to perform disease staging [53].
Transient elastography is an accurate tool for liver fibrosis
detection and has been validated for liver fibrosis assessment
in several liver diseases. A study conducted in children and
adolescents with NAFLD showed that transient elastography
is an accurate and reproducible methodology for identifying
children without fibrosis or with advanced fibrosis [49]. How-
ever, this tool is unable to discriminate between intermediate
degrees of fibrosis and thus unsuited for providing reliable
disease stage indications [47].
Liver biopsy
Liver biopsy remains the gold standard in NAFLD diagnosis.
Indeed, this is the only way to distinguish between simple
steatosis and NASH, to determine the severity of liver damage
and inflammatory activity, and to assess the degree of fibrosis.
Yet liver biopsy is an invasive method that may be associated
with complication, such as bleeding. Therefore, research has
been undertaken to develop non-invasive tools capable of
monitoring disease evolution and therapeutic responses.
Histology remains also a useful tool to exclude other causes
of chronic liver disease, as mentioned above.
Development of non-invasive tools
Certain clinical parameters, such as age, insulin resistance,
BMI, waist circumference, and lipid and glucose profiles, may
be useful for identifying children with potentially severe
NAFLD [66]. The pediatric NAFLD fibrosis index (PNFI)
was developed on the basis of three clinical parameters: age,
waist circumference, and triglyceride levels. This index aims
to predict liver fibrosis in children with NAFLD [41]. Al-
though the index provides a good positive predictive value, its
negative predictive value for ruling out fibrosis is not optimal.
Recently, the combination of the enhanced liver fibrosis
test and PNFI has proved relatively accurate for predicting
liver fibrosis in children with NAFLD [6]. The enhanced liver
fibrosis test includes a panel of serum markers that are extra-
cellular matrix components, namely the tissue inhibitor of
metalloproteinase-1, hyaluronic acid, and amino-terminal
propeptide of type III collagen.
Biomarkers related to hepatocyte apoptosis have been de-
veloped in order to stratify disease severity in pediatric
NAFLD. Caspase-generated cytokeratin-18 fragments are
specific by-products of liver cell apoptosis. Fitzpatrick et al.
showed that children with NAFLD have elevated levels of
cytokeratin-18 fragments, and that those with NASH have
markedly higher levels of cytokeratin-18 fragments [20].
Several other biomarkers of oxidative stress, inflammation,
and fibrosis are currently under investigation. However, larger
studies must be undertaken before using these markers in
pediatric clinics [19].
- NAFLD is often diagnosed in asymptomatic patients with unexplained
increased ALT levels.
- The ALT level is not correlated with NAFLD severity.
- Ultrasonography can detect steatosis when the liver contains more than
30 % fat but cannot exclude steatohepatitis or fibrosis.
- Liver biopsy remains the gold standard for the diagnosis of NAFLD.
Histology
Children with NAFLD exhibit the same morphological le-
sions as adults, namely hepatocellular injury, inflammation,
and fibrosis. However, there is a unique pattern of lesion
distribution in children. This pattern is characterized by
macrovesicular hepatocellular steatosis, portal inflammation,
and portal fibrosis in the absence of ballooning [26].
In 2005, Schwimmer et al. described two different forms of
pediatric steatohepatitis. Type 1, which is characterized by the
start of steatosis in the perivenular zone, ballooning, and
perisinusoidal fibrosis, is similar to the adult pattern. Type 2 is
characterized by periportal or panacinar steatosis, portal inflam-
mation, and portal fibrosis in the absence of ballooning. This
pattern was found in the majority of children [58]. This classi-
fication was not widely used as, a few years later, an overlap
pattern combining features of both types was found in >50 %
NAFLD children [14].
Potential mechanisms that explain the different histological
patterns between adults and children remain unclear. Howev-
er, a recent study by Swiderska-Syn et al. hypothesized that
the Hedgehog pathway, which is involved in fibro-ductular
response, may account for the unique histological features of
pediatric NAFLD. In fact, the portal and periportal compart-
ments of pre-pubescent male livers were shown to exhibit
high Hedgehog pathway activity [63].
Steatosis
Steatosis refers to the abnormal accumulation of fat in hepato-
cytes. The minimum criterion for NAFLD diagnosis is the
presence of steatosis in >5 % hepatocytes [64]. In NAFLD,
steatosis is mainly macrovacuolar. On occasion, microvacuolar
steatosis may be found [12]. In NAFLD, steatosis may also
affect the whole parenchyma.
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The pattern of steatosis distribution is different in children
than in adults. In adults, steatosis starts in the perivenular zone
(zone 3), whereas in children, it commonly begins in the
periportal zone [58].
Ballooning
Ballooning is the main morphological feature of hepatocellu-
lar damage from NASH. Ballooning is defined as a cellular
enlargement of 1.5–2 times the normal hepatocyte diameter.
The hepatocyte cytoplasm is clarified, rarefied, and may con-
tain Mallory–Denk bodies, which are eosinophilic inclusions
composed of cytoskeletal peptides aggregates. In adults, bal-
looning is usually observed in zone 3; in children, Mallory–
Denk bodies and ballooned hepatocytes are rather uncommon
[3].
Inflammation
Inflammatory infiltrates, a key marker of NASH, are usually
composed of lymphocytes, histiocytes, and Kupffer cells, with
only few granulocytes found [9]. In adults, inflammation is
prevalent in lobular spaces, whereas in children, infiltrates are
found mainly in the portal tracts [2].
Fibrosis
Fibrosis, a histological marker of chronic liver damage, typi-
cally starts in acinar zone 3 in adults, with a characteristic
chicken wire pattern. In children, fibrosis is observed mainly
in the portal–periportal tract. In advanced disease stages,
bridging fibrosis and cirrhosis may develop [11].
Scoring systems
Several scoring systems have been developed, of which
two most widely used are the Brunt Score for NASH [10]
and the NAFLD activity score, developed by the National
Institute of Diabetes and Digestive and Kidney Diseases
and the NASH Clinical Research Network for NAFLD
[25], respectively. Both systems provide a numerical score
that allows for grading disease activity and staging
fibrosis.
Since the detection of histological pattern differences be-
tween NAFLD children and adults, a new grading score
(PNHS) has been developed for pediatric NAFLD. This scor-
ing system accounts for the presence of portal inflammation,
with a weighing of each histological feature [7].
Treatment
As previously mentioned, NAFLD may progress to cirrhosis
and end-stage liver disease. Therefore, patients affected by
this condition should be treated as soon as possible.
Diet and lifestyle modifications
The first-line treatment in all NAFLD patients concerns lifestyle
modifications so as to achieve gradual weight loss. By reducing
dietary intake and increasing physical activity, patients may
achieve weight loss. These lifestyle modifications may positive-
ly impact on serum aminotransferase levels and various meta-
bolic parameters, such as insulin resistance, fasting glucose, and
lipids [46, 54]. Improvement in insulin resistance appears to be
the parameter most strongly associated with NAFLD improve-
ment. Insulin resistance can be evaluated using the homeostasis
model assessment of insulin resistance (HOMA-IR) [27].
Nobili et al. showed that liver histology significantly im-
proved following lifestyle modifications over a 24-month
period, with improvements in steatosis, inflammation, hepa-
tocyte ballooning, and NAFLD activity score observed [45].
It should, however, be noted that children’s diets must be
well-balanced, with respect of the food pyramid principle, in
order to promote harmonic growth. A follow-up by a dietician is
therefore crucial.
Currently, no evidence-based guidelines that recommend a
particular diet or exercise are available. However, a reduction in
fast-release carbohydrate consumption, especially that of fruc-
tose, is advised not only to improve insulin resistance and reduce
lipogenesis, but also to counteract the pro-inflammatory and
fibrogenic effects of fructose [1].
Yet, compliance to such lifestyle modifications is often
poor, especially in adolescents. A multidisciplinary approach
and a support by a dietician may be helpful in order to assess
diet quality and measure caloric intake.
Bariatric surgery has been shown to improve liver damage
in adults [70]. However, very few data are available for
adolescents. Standardization of eligibility criteria for adoles-
cents and further studies on safety and long-term efficacy of
this approach are warranted [48].
Pharmacotherapy
To avoid severe organ damage, pharmacological therapies
must be developed for children who do not adhere to or are
unresponsive to lifestyle modifications.
Vitamin E
In pediatric studies, vitamin E efficacy was shown not to be
superior to lifestyle changes alone [67, 69]. In a larger and
more recent study (TONIC study), the effects of vitamin E,
metformin, or placebo were assessed in NAFLD children.
Although vitamin E treatment was not superior to placebo in
terms of ALT level reduction, histological hepatocellular bal-
looning was shown to be improved under vitamin E treatment
in children with biopsy-proven NASH [28].
Eur J Pediatr (2014) 173:131–139 135
Metformin
Metformin, an insulin-sensitizing agent, lowers hepatic glu-
cose production and promotes glucose uptake in muscles. In
2005, Schwimmer et al. documented a hepatic steatosis re-
duction, evaluated using magnetic resonance spectroscopy
and ALT levels, in non-diabetic children with biopsy-proven
NASH who were treated with metformin 500 mg twice daily
for 24 weeks [60]. A 2009 study, involving a cohort of 50
obese, multi-ethnic, and insulin-resistant adolescents, showed
improvements in fatty liver prevalence and severity and in
fasting insulin levels in metformin-treated patients in compar-
ison with placebo-treated patients [39]. However, in a pediat-
ric study comparing metformin with lifestyle interventions,
Nobili et al. were not able to confirm metformin’s advantages
in NAFLD [44]. More recently, the TONIC study demonstrat-
ed that neither metformin nor vitamin E was superior to
placebo in reducing ALT levels, whereas both approaches
improved hepatocellular ballooning, with no significant im-
provements observed among other histological features [28].
Ursodeoxycholic acid
Ursodeoxycholic acid (UDCA), a hepatoprotective agent, is
assumed to prevent NAFLD progression by protecting hepa-
tocytes from bile salt-mediated mitochondrial injury, activat-
ing anti-apoptotic signalling pathways, and fulfilling immu-
nomodulatory functions.
The potential efficacy of UDCA was evaluated in a ran-
domized controlled trial involving 31 NAFLD children. In
this study, UDCA (10 mg/kg/day) was shown to be ineffective
in treating liver abnormalities in obese children [65].
Probiotics
With growing evidence that gut microbiota contributes to
NAFLD progression, probiotics have been considered for
NAFLD treatment. Studies undertaken on NAFLD animal
models suggested that probiotics may reduce liver inflamma-
tion and improve gut epithelial barrier function [13, 18]. In
2005, Loguerico et al. evaluated the effect of a probiotic
(VSL#3) in patients with chronic hepatopathies, including
NAFLD. In this study, probiotics were shown to reduce liver
injury and improve liver function tests [31]. In 2011, a double-
blind, placebo-controlled pilot study was performed in obese
children with persisting hypertransaminasemia and ultrasono-
graphic bright liver. In this study, patients receiving probiotic
therapy (Lactobacillus GG) exhibited a significant improve-
ment in serum ALT and anti-peptidoglycan polysaccharide
antibody levels that was independent of changes in BMI z
score and visceral fat [68]. Based on these study findings,
probiotics may be considered a promising tool for pediatric
NAFLD treatment.
Polyunsaturated fatty acids
Polyunsaturated fatty acids include essential fatty acids, such
as omega-3 and omega-6. Recent studies, performed in
NAFLD animal models and in adults, evaluated the effects
of oral therapy using omega-3 fatty acids. These studies
demonstrated fatty acids’ anti-inflammatory and insulin-
sensitizing properties, suggesting their potential role in
NAFLD treatment [35]. In a recent double-blind, randomized,
controlled trial conducted in children with NAFLD, a 6-month
treatment with omega-3-docosahexaenoic acid (DHA) was
reported to improve liver steatosis and insulin sensitivity, with
no significant differences observed between the 250 and
500 mg/day doses [42]. These positive results were confirmed
after a 24-month treatment period. Moreover, in the DHA-
treated groups, triglyceride levels were lower after a 24-month
treatment period, with lower ALT levels observed after a 12-
month treatment period [40].
Novel therapeutic targets
Pentoxifylline, a phosphodiesterase inhibitor, antagonizes the
TNF-alpha pathway. In NASH adults, this treatment was
shown to promote a reduction in serum ALT levels and an
improvement in histological features [30].
Farnesoid X receptors (FXR), which are expressed in the
bowel and liver, are likely involved in NAFLD pathogenesis
by mediating control of lipid and glucose homeostasis and
bacterial flora growth. A reduction in hepatic inflammation
and fibrogenesis may be induced through various mecha-
nisms, and FXR agonists may have a potential role in NAFLD
treatment. However, further studies must be undertaken before
this agent can be considered a valid NAFLD treatment [23].
Toll-like receptors (TLR) are implicated in the pathogene-
sis of NAFLD. TLR stimulation results in inflammatory re-
sponse activation, which plays a role in the progression of
NAFLD to NASH. Therefore, TLR antagonists may prove to
be potential therapeutic targets for pediatric NAFLD. Howev-
er, further studies are required to support this hypothesis [37].
Incretin mimetics and dipeptidyl peptidase-4 (DPP-4) in-
hibitors increase insulin secretion. Glucagon-like peptide-1
(GLP-1), which is an incretin secreted in response to food
intake, stimulates insulin secretion and inhibits glucagon re-
lease. DPP-4 is an enzyme implicated in the degradation of
circulating GLP-1. Studies conducted in animals and in hu-
man adults demonstrated the efficacy of GLP-1 receptor ago-
nists, which were resistant to DPP-4 degradation or DPP-4
inhibitors. These pharmacological agents represent potentially
new therapeutic approaches to NAFLD treatment by
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increasing fatty acid oxidation, decreasing lipogenesis, and
improving hepatic glucose metabolism [29].
Nowadays, there is no real consensus on the treatments for
pediatric NAFLD. The benefits of the lifestyle modifications
have widely been accepted. However, some controversies
persist concerning the pharmacological treatments. The best
way to manage this condition is may be to adapt the treatment
to each patient, considering also existing co-morbidities (such
as insulin resistance or diabetes mellitus for which metformin
can be useful). Vitamin E, probiotics, and polyunsaturated
fatty acids emerge as potentially useful treatments, although
appropriate controlled studies remain necessary before their
universal recommendation.
We propose an algorithm for the management of pediatric
NAFLD, in order to help pediatricians facing the problem of
this condition (Fig. 2).
- Lifestyle modifications represent the first-line treatment of NAFLD.
They can have a positive impact on ALT levels and can improve liver
histology.
- A reduction in fast-release carbohydrates consumption (especially
fructose) is advised.
- A multidisciplinary approach is crucial.
- Pharmacological treatments should be considered for patients who do
not adhere or are unresponsive to lifestyle modifications.
Conclusion
While pediatric NAFLD is an increasing public health
issue, this condition is still underdiagnosed, as NAFLD
pediatric patients are often asymptomatic. Over the
course of the disease, NAFLD may progress to NASH
and end-stage liver disease. Therefore, it is crucial to
diagnose and treat this condition at an early stage, and
high-risk population screening should be performed.
Liver biopsy remains the gold standard for NAFLD
diagnosis and staging. Although some non-invasive tools
have recently been developed for monitoring disease evolu-
tion and therapeutic response, there is an urgent need for new
tools that are suitable for large-scale pediatric NAFLD
screening.
First-line therapy focuses on diet and lifestyle modifica-
tions, and to this end, a multidisciplinary approach is recom-
mended. However, in the case of poor compliance or in the
absence of response to lifestyle changes, pharmacological
therapies should be initiated in order to prevent severe organ
damage. Further basic research studies are required in order to
identify new therapeutic targets.
Finally, the role of the pediatrician is also to detect the
overweight among their patients and to give them advices in
order to prevent obesity and subsequently NAFLD.
Elevated ALT Obesity or other components of the metabolic syndrome
NAFLD versus other liver disease
Normalization of the ALT Persistent elevated ALT
Follow up and prevention Ultrasonography
Transient elastography





Lifestyle changes +/- pharmacological treatment
Elevated ALT
Fig. 2 Clinical algorithm for the management of pediatric NAFLD. In
case of unexplained elevated ALT, of obesity, and/or of other
comorbidities (insulin resistance, dyslipidemia, diabetes mellitus, hyper-
tension), we recommend to perform a dosage of the liver transaminases.
In case of normalization of the liver tests, the child has to be followed
regularly by his pediatrician and a prevention should be introduced (diet
and exercise). If the ALT remain elevated, an ultrasonography (and if
necessary, a transient elastography) is recommended in order to detect the
presence of steatosis. Other causes of liver diseases should also be
excluded. If NAFLD is suspected or if the etiology of the liver disease
remains unclear, a liver biopsy is recommended in order to detect the
presence of inflammation and/or fibrosis, to stage the disease, and to
confirm the diagnosis. If the diagnosis of NAFLD is confirmed, lifestyle
changes represent the first-line treatment. Pharmacological treatments can
be considered for patients who do not adhere to or are unresponsive to
lifestyle modifications
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